<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aggressive B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of the gastrointestinal tract include Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the clinical characters of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> of the gastrointestinal (GI) tract, 101 cases of aggressive B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the GI tract were analyzed by immunohistochemistry and fluorescence in situ hybridization (FISH) using break apart probe for c-MYC gene </plain></SENT>
<SENT sid="2" pm="."><plain>For cases with c-MYC rearrangement, additional FISH studies with MYC/IgH fusion probe, BCL2 break apart probe, and BCL6 break apart probe were performed </plain></SENT>
<SENT sid="3" pm="."><plain>MYC rearrangement was detected in 23 of 101 cases of aggressive B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (22.5%) </plain></SENT>
<SENT sid="4" pm="."><plain>The cases with MYC rearrangement were divided into 14 BL, three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, and six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>One of the three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> had double translocation for MYC and BCL6 gene </plain></SENT>
<SENT sid="6" pm="."><plain>Clinically, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> of the GI tract was more akin to Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> than it is to GI tract <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> with c-MYC rearrangement </plain></SENT>
<SENT sid="7" pm="."><plain>The overall prognosis of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> was the worst among aggressive B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is uncommon category of B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in the GI tract with aggressive clinical course despite of intensive chemotherapy </plain></SENT>
</text></document>